ALEC Live signals | Maximize Profits with Getagraph.com

SELL 100739 min ago

@ $6.07

Issued: 13 Feb 2024 @ 15:46

Return: -11.94%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -2.10 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 15:45):

Stats
Today's Volume	320 411
Average Volume	684 024
Market Cap	511.78M
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.480 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.43
ATR14	$0.0110 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Altmeyer Mark	Buy	41 250	Common Stock
2024-03-19	Altmeyer Mark	Buy	19 420	Stock Option (right to buy)
2024-03-19	Desouza Errol B	Buy	41 250	Common Stock
2024-03-19	Desouza Errol B	Buy	19 420	Stock Option (right to buy)
2024-03-19	Altmeyer Mark	Sell	0	No securities of the Issuer are beneficially owned.

INSIDER POWER
-15.50
Last 100 transactions
Buy: 2 733 277 \| Sell: 3 561 219

Volume Correlation

Long: 0.14 (neutral)

Short: -0.91 (very strong negative)

Signal:(49.981) Neutral

Alector Inc Correlation

10 Most Positive Correlations
UEIC	0.946
INGN	0.946
SPTN	0.942
NKTR	0.94
SSP	0.938
TUEM	0.931
AADI	0.931
MQ	0.929
GBNH	0.928
BAND	0.927

10 Most Negative Correlations
XLRN	-0.935
ALR	-0.917
ORTX	-0.917
FLMN	-0.917
CPTA	-0.916
TYHT	-0.911
HILS	-0.91
MYRG	-0.909
INOD	-0.909
RESN	-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alector Inc Correlation - Currency/Commodity

-0.76
( moderate negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.68
( moderate negative )

0.00
( neutral )

0.79
( moderate )

Alector Inc Financials

Annual	2023
Revenue:	$97.06M
Gross Profit:	$88.21M (90.88 %)
EPS:	$-1.560

Q4	2023
Revenue:	$15.19M
Gross Profit:	$8.60M (56.62 %)
EPS:	$-0.490

Q3	2023
Revenue:	$9.11M
Gross Profit:	$6.85M (75.22 %)
EPS:	$-0.530

Q2	2023
Revenue:	$56.21M
Gross Profit:	$53.98M (96.03 %)
EPS:	$0.0165

Financial Reports:

No articles found.

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.